Clinical Report: BFJPM Reduces OVA-Induced Food Allergy Symptoms in Mice
Overview
BufeiJianpi Mixture (BFJPM) demonstrated significant efficacy in reducing food allergy symptoms and serum IgE levels in an OVA-induced murine model. Additionally, BFJPM altered gut microbiota composition, suggesting a potential therapeutic pathway for managing food allergies.
Background
Food allergies (FA) are increasingly prevalent, particularly among children, with IgE-mediated reactions being the most common. Current management strategies often involve allergen avoidance and immunotherapy, which have limitations. Understanding the role of gut microbiota in FA may provide new avenues for treatment, especially with herbal formulations like BFJPM that have shown promise in clinical practice.
Data Highlights
Group
Allergy Symptom Score
Total IgE Levels
V/C Ratio
BFJPM-L
Reduced
Lowered
Improved
BFJPM-M
Reduced
Lowered
Improved
BFJPM-H
Reduced
Lowered
Improved
Key Findings
BFJPM significantly reduced allergy symptom scores in FA mice.
Serum total IgE levels were lowered in mice treated with BFJPM.
BFJPM improved the V/C ratio of the small intestinal mucosa.
Gut microbiota analysis revealed increased richness and altered community structure with BFJPM treatment.
Saccharopolyspora was identified as a key genus associated with BFJPM intervention.
IL6, TNF, and IL10 were identified as major targets of BFJPM in food allergy management.
Clinical Implications
The findings suggest that BFJPM may serve as a complementary therapeutic option for managing food allergies, particularly in pediatric populations. The modulation of gut microbiota could be an important mechanism underlying its efficacy, warranting further investigation into its clinical applications.
Conclusion
BFJPM shows promise in alleviating food allergy symptoms and modifying gut microbiota composition in a murine model. Further studies are needed to explore its potential in clinical settings and the relationship between microbiota changes and therapeutic outcomes.
